Capmatinib Recruiting Phase 1 Trials for EGFR-mutant Non-small Cell Lung Cancer Treatment

IndicationsStatusPurposePhase
RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT03333343Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC